Rasagiline for treatment of Parkinson's disease
HAYES, Inc.
Record ID 32006001581
English
Authors' objectives:
Rasagiline mesylate (Azilect, known as TVP-1012 in clinical trials; Teva Pharmaceutical Industries Ltd.) has been investigated for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) as an initial monotherapy and as an adjunct therapy to levodopa. This drug inhibits the monoamine oxidase type B enzyme that breaks down dopamine in the brain, thereby allowing dopamine to accumulate in surviving nerve cells and reducing symptoms of PD. Rasagiline may also have other effects that could be protective, such as limiting the formation of toxic hydroxyl radicals.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com/
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Monoamine Oxidase
- Parkinson Disease
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.